SK283674B6 - Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje - Google Patents
Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje Download PDFInfo
- Publication number
- SK283674B6 SK283674B6 SK1114-95A SK111495A SK283674B6 SK 283674 B6 SK283674 B6 SK 283674B6 SK 111495 A SK111495 A SK 111495A SK 283674 B6 SK283674 B6 SK 283674B6
- Authority
- SK
- Slovakia
- Prior art keywords
- crystalline
- free acid
- ceftiofur
- oil
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
Description
1 ........ ........... | Uhol dve-théta** | (stupeň) 1 | 1-----------------------------r J Vzdialenosť d { | (Angstrdm) | | -----------------------------------------------------------------------------------------------, Relatívna intenzita*’$| (relatívne Jednotky) l |
1 —— | 38,45* | | 2,339 | | 65 | |
| 38,20 | 1 2,354 | | 25 | |
1 36,85 | 1 2,437 | | 13 1 |
| 35,35 | 1 2.833 1 | 25 | |
| 32,35 | | 2,765 | | 26 | |
| 28,30 | | 3,151 | | 31 1 |
| 27,80 | 1 3,206 I | 28 | |
| 27,15 | | 3,282 | | 40 | |
| 25,65 | | 3,470 | | 95 | |
1 25,25 | | 3,524 | | 68 | |
1 24,45 | I 3,638 1 | 53 | |
| 23,50 | | 3,783 | | 40 | |
1 21,60 | 1 1 | 60 | |
| 21,40 | 1 | | 48 | |
| 19,85 | | 4,469 | | 70 | |
1 18,15 | I 4,884 I | 56 1 |
| 15,30 | I 5,786 I | íoo | |
| 14,50 | | 6,104 | | 37 | |
1 10,55 | | 8,379 I | 35 | |
| 8,60 1 | j 10,273 j 1 Ľ | 29 | l |
difrakčný pík hliníkovej mištičky |
1----------------------------------------------j. [Vlastnosti | 1 1 1 1 1 i | Kryštalická ) voľná | kyselina | 1 | ------------------r Amorfná | voľná | kyselina J I | Kryštalická ] soľ | hydiochloridu [ 1 |
1 1 [Terraická | | 1 začiatok=212°C| | 1 začiatok=144°C| | 1 začiatok»187°C| |
| stabilita ] | 1 | 1 | 1 |
|(teplota f | plk-222°C | | plk-177»C | | plk-192°C | |
|rozkladu DSC) | 1 I | 1 1 | 1 1 | 1 1 |
1 1 (Rozpustnosť | | 1 -0 mg/ral | | -----------M ...o- | -100 mg/ntl | | 1 100 mg/ml | |
| -PH7 | 1 1 | 1 1 | 1 1 | 1 1 |
1 1 |Rýchlosť ( | 1 nÍ2ka | | 1 vysoká | | 1 vysoká | |
[rozpúšťania* | 1 I | 1 l | i 1 | 1 1 |
1 1 [Uvolňovanie | | 1 predĺžené | | 1 rýchle | | 1 rýchle | |
]in vivo | | 1 | 1 1 | 1 t |
[Čistota J 1 1 | vysoká | 1 | I nízka | | 1 vysoká | 1 |
1 1 [Stabilita vo ) | 1 stabilné J | nestabilné | | 1 nestabilné [ |
(vodných formúl| | 6 mesiacov | | do 6 | | do 6 | |
|(>90% pôvodnej[ I t | 1 1 | týždňov | | týždňov | 1 |
1-------------------------------------1- |Hygroskop. | I t | 1 nízka | 1 | vysoká | 1 | 1 stredná [ 1 |
1--------------------r [Spracovanie | | 1 IahSie sa [ | 1 ťažko sa J | • 1 ľahšie sa | |
1 1 i | mikromelie | L- | mikromelie | | mikromelie| ____________________________________________________________1 |
Claims (23)
- PATENTOVÉ NÁROKY ktorá je kyselinou 7-[2-(2-amino-l,3-tiazol-4-yl)-2-metoxyimino)acetamido]-3-[(fur-2-ylkarbonyl)tiometyl]-3-cefem-4-karboxylovej.
- 2. Kryštalická voľná kyselina ceftiofuru podľa nároku1, vyznačujúca sa tým, že má nasledovné vlastnosti stanovené rôntgenovou práškovou difrakciou:| Uhol dve-théta** | Vzdialenosť d [ Relatívna intenzita*»$| j (stupeň) | (Angstrtta) | (relatívne jednotky) j
33,45* | 2,339 | 65 38,20 | 2,354 | 25 33,85 | 2,437 | 13 35,35 | 2.537 | 25 32,35 | 2,765 | 26 28,30 | 3,151 | 31 27,80 | 3,206 | 28 27,15 | 3,282 | 40 25,65 | 3,470 | 95 25,25 | 3,524 | 68 24,45 | 3,638 | 53 23,50 | 3,783 | 40 21,60 | 4,111 | 60 21,40 j 4,149 | 48 19,85 ] 4,469 | 70 18,15 | 4,884 | 56 15,30 | 5,786 | 100 14,50 | 6,104 | 37 10,55 | 8,379 | 35 8,60 | 10,273 | 29 I_________________________________________________________________________________________I-----------------------------------------------------------------------1------------------------------------------------------------------------------------------------------1 *: difrakčný pík hliníkovej mištičky **:_+ 0,10° #: Relatívna intenzita pre každý pík sa stanovila z pomeru jeho intenzity k intenzite najsilnejšieho piku pri difrakčnom uhle 15,3°, ktorého hodnota sa zvolila 100.V tabuľke sú dané iba tie piky, ktoré mali relatívnu intenzitu väčšiu ako 10. - 3. Farmaceutická kompozícia zahrnujúca kryštalickú voľnú kyselinu ceftiofuru vzorca (I), podľa nároku 1 vyznačujúca sa tým, že kryštalický podiel vo voľnej kyseline ceftiofuru vzorca (I) predstavuje aspoň štyridsať percent.
- 4. Farmaceutická kompozícia podľa nároku 3, v y značujúca sa tým, že ďalej obsahuje farmaceutický prijateľný nosič alebo excipient.
- 5. Farmaceutická kompozícia podľa nároku 3, vyzná í u j ú c a sa tým, že kryštalický podiel vo voľnej kyseline ceftiofuru vzorca (I) predstavuje aspoň päťdesiat percent.
- 6. Farmaceutická kompozícia podľa nároku 5, vyzná í u j ú c a sa tým, že kryštalický podiel vo voľnej kyseline ceftiofuru vzorca (I) predstavuje aspoň sedemdesiat percent.
- 7. Farmaceutická kompozícia podľa nároku 3, vyzná í u j ú c a sa tým, že obsahuje kryštalickú voľnú kyselinu ceftiofuru vzorca (I).
- 8. Farmaceutická kompozícia podľa nároku 7, v y značujúca sa tým, že ďalej obsahuje farmaceutický prijateľný nosič alebo excipient.
- 9. Farmaceutická kompozícia podľa nároku 7, vyznačujúca sa tým, že je to kompozícia s trvalým uvoľňovaním.
- 10. Farmaceutická kompozícia podľa nároku 7, vyzná í u j ú c a sa tým,že obsahuje 20 až 200 mg/ml kryštalickej voľnej kyseliny ceftiofuru vzorca (I).
- 11. Farmaceutická kompozícia podľa nároku 7, vyznač u j ú c a sa tým, že je vo forme vhodnej na injekčné subkutánne alebo intramuskuláme podávanie.
- 12. Farmaceutická kompozícia podľa nároku 7, vyznačujúca sa tým, že je bezvodá.
- 13. Farmaceutická kompozícia podľa nároku 12, vyzná č u j ú c a sa tým, že obsahuje olej.
- 14. Kompozícia podľa nároku 13, vyznačujúca sa tým, že olej je vybraný zo skupiny, ktorú tvoria: kukuričný olej, arašidový olej, sezamový olej, olivový olej, palmový olej, saflorový olej, sójový olej, olej zo semien bavlníka, repkový olej, slnečnicový olej a ich zmesi.
- 15. Spôsob prípravy kryštalickej voľnej kyseliny ceftioíuru vzorca (I), podľa nárokov 1 až 2 oI OCH, vyznačujúci sa tým, že zahrnuje nasledovné kroky:a) zmiešanie roztoku zlúčeniny vzorca (I) v rozpúšťadle, ktoré je miešateľné s vodou a je vybrané zo skupiny, ktorú tvorí acetón, tetrahydrofúrán a etanol, pričom voda má teplotu v rozmedzí 20 °C až 60 °C.
- 16. Spôsob prípravy podľa nároku 15, vyznačujúci sa tým, že rozpúšťadlo je tetrahydrofúrán (THF).
- 17. Spôsob prípravy podľa nároku 15, vyznačujúci sa tým, že voda má teplotu v rozmedzí medzi 40 “C a 60 °C.
- 18. Spôsob prípravy podľa nároku 17, vyznačujúci sa tým, že teplota vody je približne 50 °C.
- 19. Spôsob prípravy podľa nároku 16, vyznačujúci sa tým, že pomer vody k THF roztoku voľnej kyseliny ceftiofuru vzorca (I) je v rozmedzí 10 : 1 až 2 : 1.
- 20. Spôsob prípravy podľa nároku 19, vyznačujúci sa tým, že pomer vody k THF roztoku voľnej kyseliny ceftiofuru vzorca (I) je 3 : 1.
- 21. Spôsob prípravy podľa nároku 15, vyznačujúci sa tým, že ďalej zahrnuje:b) miešanie reakčnej zmesi, ktorá sa získa v kroku a) počas v časovom rozmedzí medzi tridsať minút až dvadsaťštyri hodín.
- 22. Spôsob prípravy podľa nároku 21, v y z n a č u j ú c i sa t ý m , že čas miešania je v rozmedzí medzi tridsať minút až štyri hodiny.
- 23. Spôsob prípravy podľa nároku 22, vyznačujúci sa tým, že čas miešania je v rozmedzí medzi tridsať minút až jednou hodinou.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3329193A | 1993-03-12 | 1993-03-12 | |
PCT/US1994/001862 WO1994020505A1 (en) | 1993-03-12 | 1994-03-07 | Crystalline ceftiofur free acid |
Publications (2)
Publication Number | Publication Date |
---|---|
SK111495A3 SK111495A3 (en) | 1995-12-06 |
SK283674B6 true SK283674B6 (sk) | 2003-11-04 |
Family
ID=21869579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1114-95A SK283674B6 (sk) | 1993-03-12 | 1994-03-07 | Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje |
Country Status (31)
Country | Link |
---|---|
US (1) | US5721359A (sk) |
EP (1) | EP0690864B1 (sk) |
JP (1) | JP3852946B2 (sk) |
KR (1) | KR100296810B1 (sk) |
CN (1) | CN1055090C (sk) |
AT (1) | ATE202109T1 (sk) |
AU (1) | AU694419B2 (sk) |
BR (1) | BR1101034A (sk) |
CA (1) | CA2155322C (sk) |
CZ (1) | CZ289332B6 (sk) |
DE (2) | DE122005000055I2 (sk) |
DK (1) | DK0690864T3 (sk) |
ES (1) | ES2157254T3 (sk) |
FI (1) | FI120307B (sk) |
FR (1) | FR05C0045I2 (sk) |
GR (1) | GR3036514T3 (sk) |
HU (1) | HU222244B1 (sk) |
IL (1) | IL108910A (sk) |
LU (1) | LU91206I2 (sk) |
LV (1) | LV12889B (sk) |
NL (1) | NL300208I2 (sk) |
NO (2) | NO313199B1 (sk) |
NZ (1) | NZ263002A (sk) |
PL (1) | PL184611B1 (sk) |
PT (1) | PT690864E (sk) |
RU (1) | RU2136685C1 (sk) |
SI (1) | SI0690864T1 (sk) |
SK (1) | SK283674B6 (sk) |
TW (1) | TW267170B (sk) |
WO (1) | WO1994020505A1 (sk) |
ZA (1) | ZA941586B (sk) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736151A (en) * | 1996-12-09 | 1998-04-07 | Pharmacia & Upjohn Company | Antibiotic oil suspensions |
US6074657A (en) * | 1997-03-20 | 2000-06-13 | Pharmacia & Upjohn Company | Administration of an injectable antibiotic in the ear of an animal |
US7829100B2 (en) * | 2000-09-12 | 2010-11-09 | Teagarden Dirk L | Pharmaceutical composition having modified carrier |
NZ524694A (en) * | 2000-09-12 | 2005-05-27 | Upjohn Co | Pharmaceutical composition having modified carrier |
KR100423895B1 (ko) * | 2001-02-19 | 2004-03-24 | 주식회사 엘지생명과학 | 셉티오퍼 하이드로클로라이드의 현탁제 조성물 |
MXPA04000294A (es) * | 2001-07-10 | 2004-05-04 | Pharmacia & Upjhon Company | Tiacin oxazolidinonas cristalinas. |
CA2455050C (en) | 2001-08-15 | 2007-02-20 | Pharmacia & Upjohn Company | Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
US20030181398A1 (en) † | 2002-03-21 | 2003-09-25 | Brown Scott A. | Method of administering an injectable antibiotic to an animal |
US20040022815A1 (en) * | 2002-08-05 | 2004-02-05 | Orchid Health Care | Novel pharmaceutical composition of ceftiofur |
KR20040015622A (ko) * | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물 |
US20040115822A1 (en) * | 2002-09-12 | 2004-06-17 | Schapaugh Randal Lee | Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition |
US7659061B2 (en) * | 2002-11-19 | 2010-02-09 | Pharmacia & Upjohn Company | Pharmaceutical compositions having a modified vehicle |
US20040115837A1 (en) * | 2002-11-27 | 2004-06-17 | Schapaugh Randal Lee | Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition |
US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
ES2329244T3 (es) * | 2003-03-27 | 2009-11-24 | Basilea Pharmaceutica Ag | Cefalosporina en forma cristalina. |
US8039482B2 (en) | 2004-03-25 | 2011-10-18 | Astellas Pharma Inc. | Composition of solifenacin or salt thereof for use in solid formulation |
US7815939B2 (en) | 2005-07-20 | 2010-10-19 | Astellas Pharma Inc. | Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms |
BRPI0617561A2 (pt) * | 2005-10-12 | 2011-08-23 | Orchid Chemicals & Pharm Ltd | sal de sódio cristalino antibiótico de cefalosporina |
US8470809B2 (en) * | 2005-10-12 | 2013-06-25 | Orchid Chemicals & Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
CN101835750B (zh) | 2007-08-22 | 2013-07-17 | 阿斯利康(瑞典)有限公司 | 环丙基酰胺衍生物 |
EP2303026B1 (en) | 2008-06-17 | 2020-09-09 | Brigham Young University | Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
WO2010020871A2 (en) * | 2008-08-22 | 2010-02-25 | Orchid Chemicals & Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
CA2743551C (en) * | 2008-11-19 | 2017-08-15 | Merial Limited | Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol |
SG172926A1 (en) * | 2009-01-30 | 2011-08-29 | Glaxosmithkline Llc | Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
BR112012020780A2 (pt) * | 2010-02-18 | 2016-05-03 | Astrazeneca Ab | forma sólida, composição farmacêutica, e, uso de uma forma sólida. |
BR112012020629A2 (pt) | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | forma cristalina, e, método para a terapia de um distúrbio |
CA2834999A1 (en) * | 2011-05-02 | 2012-11-08 | Zoetis Llc | Novel cephalosporins useful as antibacterial agents |
CN104039369B (zh) | 2011-07-20 | 2017-06-16 | 布莱阿姆青年大学 | 疏水性塞拉集宁化合物和包含该化合物的装置 |
EP2760454B1 (en) | 2011-09-13 | 2018-08-29 | Brigham Young University | Products for healing of tissue wounds |
US9603859B2 (en) | 2011-09-13 | 2017-03-28 | Brigham Young University | Methods and products for increasing the rate of healing of tissue wounds |
US9694019B2 (en) | 2011-09-13 | 2017-07-04 | Brigham Young University | Compositions and methods for treating bone diseases and broken bones |
CN104080459B (zh) | 2011-09-13 | 2018-07-03 | 布莱阿姆青年大学 | 用于治疗骨疾病和断骨的组合物 |
CA2859325A1 (en) | 2011-12-21 | 2013-07-25 | Brigham Young University | Oral care compositions |
CN102584855B (zh) * | 2012-02-16 | 2014-06-25 | 青岛科技大学 | 一种改进的头孢噻呋的制备方法 |
US9533063B1 (en) | 2012-03-01 | 2017-01-03 | Brigham Young University | Aerosols incorporating ceragenin compounds and methods of use thereof |
US10039285B2 (en) | 2012-05-02 | 2018-08-07 | Brigham Young University | Ceragenin particulate materials and methods for making same |
BR112015008804A2 (pt) | 2012-10-17 | 2017-07-04 | Univ Brigham Young | tratamento e prevenção de mastite |
WO2014087972A1 (ja) * | 2012-12-03 | 2014-06-12 | 株式会社カネカ | 還元型補酵素q10誘導体およびその製造方法 |
WO2014107740A2 (en) | 2013-01-07 | 2014-07-10 | Brigham Young University | Methods for reducing cellular proliferation and treating certain diseases |
US10568893B2 (en) | 2013-03-15 | 2020-02-25 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
BR112015023747B1 (pt) | 2013-03-15 | 2023-04-18 | Brigham Young University | Uso de um composto antimicrobiano catiônico esteroide (csa) para a preparação de uma composição para tratar, reduzir, ou prevenir inflamação aguda ou crônica e/ou dor aguda ou crônica associada com uma doença ou um sintoma de doença |
US11524015B2 (en) | 2013-03-15 | 2022-12-13 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
RU2546675C2 (ru) * | 2013-04-11 | 2015-04-10 | Федеральное казённое предприятие "Государственный научно-исследовательский институт химических продуктов" (ФКП "ГосНИИХП") | Способ определения степени кристалличности составов на основе дифениламина |
US9387215B2 (en) | 2013-04-22 | 2016-07-12 | Brigham Young University | Animal feed including cationic cholesterol additive and related methods |
EP3042893B1 (en) * | 2013-09-05 | 2018-10-31 | Mitsubishi Tanabe Pharma Corporation | Novel crystalline arylalkylamine compound and method for producing same |
US11690855B2 (en) | 2013-10-17 | 2023-07-04 | Brigham Young University | Methods for treating lung infections and inflammation |
US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
CA2844321C (en) | 2014-02-27 | 2021-03-16 | Brigham Young University | Cationic steroidal antimicrobial compounds |
US10220045B2 (en) | 2014-03-13 | 2019-03-05 | Brigham Young University | Compositions and methods for forming stabilized compositions with reduced CSA agglomeration |
US9867836B2 (en) | 2014-03-13 | 2018-01-16 | Brigham Young University | Lavage and/or infusion using CSA compounds for increasing fertility in a mammal |
US9931350B2 (en) | 2014-03-14 | 2018-04-03 | Brigham Young University | Anti-infective and osteogenic compositions and methods of use |
US9686966B2 (en) | 2014-04-30 | 2017-06-27 | Brigham Young University | Methods and apparatus for cleaning or disinfecting a water delivery system |
US10441595B2 (en) | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
US10238665B2 (en) | 2014-06-26 | 2019-03-26 | Brigham Young University | Methods for treating fungal infections |
US10227376B2 (en) | 2014-08-22 | 2019-03-12 | Brigham Young University | Radiolabeled cationic steroid antimicrobials and diagnostic methods |
US10155788B2 (en) | 2014-10-07 | 2018-12-18 | Brigham Young University | Cationic steroidal antimicrobial prodrug compositions and uses thereof |
MX2017005120A (es) * | 2014-10-21 | 2018-02-12 | Ariad Pharma Inc | Formas cristalinas de 5-cloro-n4-[-2-(dimetilfosforil) fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il] pirimidin-2,4-diamina. |
US10370403B2 (en) | 2015-04-22 | 2019-08-06 | Brigham Young University | Methods for the synthesis of ceragenins |
US9527883B2 (en) | 2015-04-22 | 2016-12-27 | Brigham Young University | Methods for the synthesis of ceragenins |
KR101753842B1 (ko) * | 2015-05-12 | 2017-07-04 | 한국화학연구원 | 불화퀴놀론계 항생제를 담지한 서방형 제제 및 이의 제조방법 |
US9434759B1 (en) | 2015-05-18 | 2016-09-06 | Brigham Young University | Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds |
CN106543203B (zh) * | 2015-09-18 | 2019-07-02 | 瑞普(天津)生物药业有限公司 | 一种长效头孢噻呋自由酸晶体的制备方法 |
CA3011323A1 (en) * | 2016-01-22 | 2017-07-27 | Sandoz Ag | Crystalline eravacycline bis-hydrochloride |
US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
KR101898282B1 (ko) * | 2016-05-24 | 2018-09-13 | 주식회사 고려비엔피 | 항생제의 서방형 수의학적 조성물 및 이의 제조방법 |
EP3481820B1 (en) | 2016-07-07 | 2023-10-18 | Cyclerion Therapeutics, Inc. | Solid forms of an sgc stimulator |
US10959433B2 (en) | 2017-03-21 | 2021-03-30 | Brigham Young University | Use of cationic steroidal antimicrobials for sporicidal activity |
US11186556B1 (en) * | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
TW202233625A (zh) * | 2020-11-18 | 2022-09-01 | 美商傳達治療有限公司 | Fgfr抑制劑及其製造及使用方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1207933B (de) * | 1962-12-26 | 1965-12-30 | American Home Prod | Verfahren zur Herstellung von kristallwasser-freiem D-alpha-Aminobenzylpenicillin |
US3489752A (en) * | 1967-09-05 | 1970-01-13 | Bristol Myers Co | 7-amino-cephalosporanic and decephalosporanic acid derivatives |
DK154939C (da) * | 1974-12-19 | 1989-06-12 | Takeda Chemical Industries Ltd | Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf |
DE2760123C2 (de) * | 1976-01-23 | 1986-04-30 | Roussel-Uclaf, Paris | 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen |
GB1532682A (en) * | 1976-04-27 | 1978-11-22 | Bristol Myers Co | Process for the preparation of cephadroxil |
FR2479229B1 (fr) * | 1980-03-26 | 1986-01-17 | Clin Midy | Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives |
IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
US4400503A (en) * | 1981-10-30 | 1983-08-23 | Eli Lilly And Company | Purification of syn-7-[[(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-3-methyl-3-cephem-4-carboxylic acid |
DE3313818A1 (de) * | 1983-04-16 | 1984-10-18 | Hoechst Ag, 6230 Frankfurt | Neue kristallmodifikation von ceftazidim |
KR890002631B1 (ko) * | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
IT1181672B (it) * | 1984-10-25 | 1987-09-30 | Upjohn Co | Cefalosporina alogenidrato cristallino |
US4902683A (en) * | 1984-10-25 | 1990-02-20 | The Upjohn Company | Crystalline cephalosporin hydrohalide salts |
US4937330A (en) * | 1985-08-12 | 1990-06-26 | The Upjohn Company | Conversion of cephalosporin hydrohalide salt to alkali metal salt |
GB8608962D0 (en) * | 1986-04-12 | 1986-05-14 | Beecham Group Plc | Beta-lactam antibiotics |
IT1214587B (it) * | 1986-12-23 | 1990-01-18 | Giovanni Bonfanti | Metodo per la produzione diprodotti cristallini puri. |
ATE76874T1 (de) * | 1987-02-02 | 1992-06-15 | Lilly Co Eli | Verfahren zur herstellung von ceftazidimepentahydrat. |
DE3869135D1 (de) * | 1987-07-29 | 1992-04-16 | Upjohn Co | Kontrollierte freisetzung von antibiotika-salzen aus einem implantat. |
AU617377B2 (en) * | 1987-11-10 | 1991-11-28 | Pharmacia & Upjohn Company | Cephalosporin antibiotics |
US4877782A (en) * | 1988-02-16 | 1989-10-31 | The Upjohn Company | Zinc ceftiofur complexes |
-
1994
- 1994-03-07 CN CN94191448A patent/CN1055090C/zh not_active Expired - Lifetime
- 1994-03-07 EP EP94910721A patent/EP0690864B1/en not_active Expired - Lifetime
- 1994-03-07 NZ NZ263002A patent/NZ263002A/en not_active IP Right Cessation
- 1994-03-07 JP JP52002594A patent/JP3852946B2/ja not_active Expired - Lifetime
- 1994-03-07 ZA ZA941586A patent/ZA941586B/xx unknown
- 1994-03-07 PT PT94910721T patent/PT690864E/pt unknown
- 1994-03-07 DE DE122005000055C patent/DE122005000055I2/de active Active
- 1994-03-07 DK DK94910721T patent/DK0690864T3/da active
- 1994-03-07 RU RU95121942A patent/RU2136685C1/ru active
- 1994-03-07 HU HU9501960A patent/HU222244B1/hu active Protection Beyond IP Right Term
- 1994-03-07 SK SK1114-95A patent/SK283674B6/sk not_active IP Right Cessation
- 1994-03-07 KR KR1019950703858A patent/KR100296810B1/ko not_active IP Right Cessation
- 1994-03-07 DE DE69427469T patent/DE69427469T2/de not_active Expired - Lifetime
- 1994-03-07 SI SI9430374T patent/SI0690864T1/xx unknown
- 1994-03-07 ES ES94910721T patent/ES2157254T3/es not_active Expired - Lifetime
- 1994-03-07 PL PL94310556A patent/PL184611B1/pl unknown
- 1994-03-07 AU AU63510/94A patent/AU694419B2/en not_active Expired
- 1994-03-07 US US08/549,821 patent/US5721359A/en not_active Expired - Lifetime
- 1994-03-07 CA CA002155322A patent/CA2155322C/en not_active Expired - Lifetime
- 1994-03-07 WO PCT/US1994/001862 patent/WO1994020505A1/en active IP Right Grant
- 1994-03-07 AT AT94910721T patent/ATE202109T1/de active
- 1994-03-07 CZ CZ19952290A patent/CZ289332B6/cs unknown
- 1994-03-09 IL IL10891094A patent/IL108910A/en not_active IP Right Cessation
- 1994-03-12 TW TW083102155A patent/TW267170B/zh not_active IP Right Cessation
-
1995
- 1995-09-11 FI FI954250A patent/FI120307B/fi not_active IP Right Cessation
- 1995-09-11 NO NO19953564A patent/NO313199B1/no not_active IP Right Cessation
-
1997
- 1997-05-14 BR BR1101034-7A patent/BR1101034A/pt active IP Right Grant
-
2001
- 2001-09-04 GR GR20010401374T patent/GR3036514T3/el unknown
-
2002
- 2002-06-13 LV LVP-02-107A patent/LV12889B/lv unknown
-
2005
- 2005-11-16 LU LU91206C patent/LU91206I2/fr unknown
- 2005-11-17 FR FR05C0045C patent/FR05C0045I2/fr active Active
- 2005-11-18 NO NO2005025C patent/NO2005025I2/no unknown
- 2005-11-21 NL NL300208C patent/NL300208I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK283674B6 (sk) | Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje | |
US6486149B2 (en) | Composition comprising a crystallographically stable, amorphous cephalosporin and processes for the preparation thereof | |
EP2870163B1 (en) | Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof | |
PL172830B1 (pl) | Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL | |
WO2006106529A1 (en) | A co-spray dried composition of cefepime with base and process for preparation thereof | |
CN112094249A (zh) | 磺胺甲噻二唑-糖精共晶及其制备方法与应用 | |
PL196046B1 (pl) | Postać krystaliczna monohydratu cytrynianu (2S,3S)-N-(2-metoksy-5-t-butylofenylo)metylo-2-difenylometylo-1-azabicyklo[2.2.2]oktano-3-aminy, środek farmaceutyczny, zastosowanie tej postaci krystalicznej i sposób wytwarzania tej postaci krystalicznej | |
RU2074858C1 (ru) | Кристаллический дигидрат (5r, 6s)-2-карбамоилоксиметил-6-[(1r)-гидроксиэтил]-2-пенем-3-карбоновой кислоты, способ его получения, фармацевтическая композиция | |
JPH01199977A (ja) | セファロスポリン誘導体の結晶、その製造法およびそれらを有効成分とする医薬組成物 | |
NZ759132A (en) | Solid forms of { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, compositions, and uses thereof | |
NZ759132B2 (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
NZ719970B2 (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
JPWO2004039816A1 (ja) | セフェム化合物の無機酸塩の結晶 | |
KR20070007766A (ko) | 3-베타-아미노 17-메틸렌 안드로스테인-6-알파 7-베타-디올하이드로클로라이드의 결정질 형태 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC4A | Assignment and transfer of rights |
Owner name: PAH P&U LLC, NEW YORK, NY, US Free format text: FORMER OWNER: PHARMACIA & UPJOHN COMPANY LLC, KALAMAZOO, MI, US Effective date: 20130619 |
|
SPCT | Transfer of rights of an spc |
Owner name: ZOETIS LLC, US Free format text: FORMER OWNER: PHARMACIA + UPJOHN COMPONY LLC,US Spc suppl protection certif: 40 7-2005 Effective date: 20130619 |
|
TC4A | Change of owner's name |
Owner name: ZOETIS P&U LLC, FLORHAM PARK, NJ, US Effective date: 20130619 |
|
TE4A | Change of owner's address |
Owner name: PHARMACIA & UPJOHN COMPANY LLC, KALAMAZOO, MI, US Effective date: 20130619 |
|
MK4A | Patent expired |
Expiry date: 20140307 |
|
SPCC | Change of address or name of an owner of an spc |
Owner name: ZOETIS SERVICES LLC, US Spc suppl protection certif: 40 7-2005 Effective date: 20170314 |
|
SPCE | Expiry of an spc |
Spc suppl protection certif: 40, PDO 7-2005 Effective date: 20190308 |